Skip to main content
峆一药业 logo

峆一药业 — Investor Relations & Filings

Ticker · 920478 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2023-09-10 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920478

About 峆一药业

http://www.heryipharma.com/

Anhui Heyi Pharmaceutical Co., Ltd. specializes in the research, development, production, and sales of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company focuses on providing high-quality chemical products for various therapeutic areas, including cardiovascular, central nervous system, and anti-infective treatments. With a strong emphasis on technological innovation and quality control, it operates advanced manufacturing facilities that adhere to international standards. Its product portfolio includes key intermediates for widely used medications, supporting both domestic and global pharmaceutical supply chains. The company leverages its expertise in complex chemical synthesis to offer customized solutions and reliable supply to its partners in the life sciences sector.

Recent filings

Filing Released Lang Actions
关于取得发明专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company about receiving an invention patent certificate from the National Intellectual Property Office. It contains no financial data, no mention of financial results, no regulatory filings related to financial performance, no meeting materials, no voting results, no management changes, no legal proceedings, no capital changes, and no other financial or governance-related content. The document is primarily an intellectual property announcement, which does not fit into any of the specific financial filing categories. Given the short length (581 characters) and the nature of the content, it is best classified under Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2023-09-10 Chinese
关于取得发明专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company about receiving an invention patent certificate from the National Intellectual Property Office. It contains no financial data, no mention of financial results, no regulatory filings related to financial performance, no meeting or voting information, and no mention of any report publication. The content is about intellectual property rights and patent grant, which does not fit into any financial report categories. It is a regulatory announcement related to company operations but not financial or governance filings. Therefore, the best fitting category is Regulatory Filings (RNS) as a fallback for miscellaneous announcements that do not fit other categories.
2023-09-10 Chinese
第四届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 11th meeting of the 4th Board of Directors of Anhui Xuyi Pharmaceutical Co., Ltd. It details the meeting date, attendance, and voting results on specific agenda items, including approval of the 2023 semi-annual report and a special report on the use of raised funds. The document references the actual semi-annual report and special report as being disclosed elsewhere (on the Beijing Stock Exchange information platform) and does not contain the financial data or substantive analysis itself. The document is primarily a board meeting resolution announcement, not the report itself. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2023-08-28 Chinese
第四届监事会第十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Anhui Xuyi Pharmaceutical Co., Ltd. It details the meeting date, attendance, and voting results on two agenda items: approval of the 2023 semi-annual report and a special report on the use of raised funds. The document references the actual semi-annual report and special report published on the Beijing Stock Exchange information disclosure platform, indicating that this document itself is not the report but an announcement of the meeting resolutions related to those reports. The document length is short (1154 characters) and it does not contain substantive financial data or the full report content. Therefore, it fits best as a Regulatory Filing (RNS) because it is a formal announcement of meeting resolutions and related disclosures, not the full interim report or financial statements themselves.
2023-08-28 Chinese
2023年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告摘要" which translates to "Half-Year Report Summary" for the year 2023. It contains detailed financial data such as total assets, net profit, earnings per share, and other financial metrics for the half-year period. It also includes company business descriptions, shareholder information, and notes on asset pledges and restrictions. The document explicitly states it is a half-year report summary derived from the full half-year report and includes substantive financial data and analysis. The length of the document (4871 characters) and the detailed financial content confirm it is a financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-28 Chinese
2023年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023 半年度募集资金存放与实际使用情况的专项报告" which translates to a "2023 Semi-Annual Special Report on the Deposit and Actual Use of Raised Funds." It details the issuance of new shares, the amount of funds raised, the management and use of these funds, including investment in financial products, and confirms compliance with relevant laws and regulations. The document is focused on the use and management of capital raised through share issuance, including detailed financial figures related to fundraising and fund usage. It is not a full annual or interim financial report but a specialized report on capital raising and fund usage. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is under 5,000 characters but contains substantive financial data and detailed explanations, so it is not merely an announcement or a report publication notice. Therefore, the correct classification is CAP with high confidence.
2023-08-28 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.